{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"5"},{"groupId":"OG010","value":"19"},{"groupId":"OG011","value":"10"},{"groupId":"OG012","value":"63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"28"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"31"},{"groupId":"OG009","value":"32"},{"groupId":"OG010","value":"100"},{"groupId":"OG011","value":"60"},{"groupId":"OG012","value":"373"}],"units":"Participants"}],"title":"On-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"44"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"17"},{"groupId":"OG009","value":"16"},{"groupId":"OG010","value":"61"},{"groupId":"OG011","value":"29"},{"groupId":"OG012","value":"231"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"42"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"55"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"20"},{"groupId":"OG009","value":"23"},{"groupId":"OG010","value":"75"},{"groupId":"OG011","value":"43"},{"groupId":"OG012","value":"296"}],"units":"Participants"}],"title":"Post-treatment efficacy/survival follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"58"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"22"},{"groupId":"OG009","value":"21"},{"groupId":"OG010","value":"80"},{"groupId":"OG011","value":"39"},{"groupId":"OG012","value":"294"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"28"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"31"},{"groupId":"OG009","value":"32"},{"groupId":"OG010","value":"100"},{"groupId":"OG011","value":"60"},{"groupId":"OG012","value":"373"}],"units":"Participants"}],"title":"All deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"28"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"31"},{"groupId":"OG009","value":"32"},{"groupId":"OG010","value":"100"},{"groupId":"OG011","value":"60"},{"groupId":"OG012","value":"373"}],"units":"Participants"}],"description":"On-treatment deaths were collected from start of treatment to 30 days after last dose of treatment.\n\nPost-treatment efficacy/survival follow-up deaths were collected from 31 days after last dose of treatment until the end of the study.\n\nAll deaths refer to the sum of on-treatment and post-treatment efficacy/survival follow-up deaths.","groups":[{"description":"Pre-treated patients with MET GCN ≥ 10 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG000","title":"Cohort 1a: Pre-treated Patients With MET GCN ≥ 10 (2/3L)"},{"description":"Pre-treated patients with MET GCN ≥ 6 and \\< 10 treated with INC280 at 400 mg BID as second or third line (2/3L)","id":"OG001","title":"Cohort 1b: Pre-treated Patients With MET GCN ≥ 6 and < 10 (2/3L)"},{"description":"Pre-treated patients with MET GCN ≥ 4 and \\< 6 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG002","title":"Cohort 2: Pre-treated Patients With MET GCN ≥ 4 and < 6 (2/3L)"},{"description":"Pre-treated patients with MET GCN \\< 4 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG003","title":"Cohort 3: Pre-treated Patients With MET GCN < 4 (2/3L)"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG004","title":"Cohort 4: Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)"},{"description":"Treatment-naïve patients with MET GCN ≥10 treated with INC280 at 400mg BID as first-line (1L)","id":"OG005","title":"Cohort 5a: Treatment-naïve Patients With MET GCN ≥10 (1L)"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L)","id":"OG006","title":"Cohort 5b: Treatment-naïve Patients With MET Mutation Regardless of MET GCN (1L)"},{"description":"Pre-treated patients with MET GCN ≥ 10 without MET mutation treated with INC280 at 400 mg BID as second line (2L) (expansion cohort of Cohort 1a)","id":"OG007","title":"Cohort 6.1 (Expansion of Cohort 1a): Pre-treated Patients MET GCN ≥ 10 Without MET Mutation (2L)"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as second line (2L)(expansion of Cohort 4)","id":"OG008","title":"Cohort 6.2 (Expansion of Cohort 4): Pre-treated Patients With MET Mutation (2L)"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L) (expansion cohort of Cohort 5b)","id":"OG009","title":"Cohort 7 (Expansion of Cohort 5b): Treatment-naïve With MET Mutation Regardless of MET GCN (1L)"},{"description":"All pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L). (Participants from Cohort 4 and Cohort 6.2)","id":"OG010","title":"Cohort 4 + Cohort 6.2: All Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)"},{"description":"All treatment naive patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as first line (1L) (Participants from Cohort 5b and Cohort 7)","id":"OG011","title":"Cohort 5b + Cohort 7: All Treatment-naive With MET Mutation Regardless of MET GCN (1L)"},{"description":"All participants","id":"OG012","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"FAS, including all subjects who received at least one dose of capmatinib","reportingStatus":"POSTED","timeFrame":"On-treatment: Up to approximately 5.5 years. Post-treatment efficacy/survival follow-up: Up to approximately 6 years","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}